Project Grant R01CA288366

Award Date 6/5/24
Completion Date 5/31/29
Dollars Obligated $1.1M
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a Phase I clinical trial to evaluate the safety and efficacy of CSPG4-targeted CAR-T cell therapy in adult patients with head and neck squamous cell carcinoma (HNSCC) that is refractory to platinum and PD-1 inhibitor treatment. The award of $627,456 will fund the single-center, open-label clinical trial over a 5-year period from December 2024 to November 2029....
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
This $429,000 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to engineer extracellular vesicles (EEVs) carrying anti-DSG2 single-chain variable fragment (scFv) fusion proteins and miR-155 for therapeutic treatment of head and neck squamous cell carcinoma (HNSCC). The award to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, will support...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,564,226 Project Grant (CFDA 93.121 - Oral Diseases and Disorders Research) to Virginia Commonwealth University (VCU) to investigate the role of FOSL1 super-enhancers in cisplatin-enriched cancer stem cells (CSCs) in head and neck squamous cell carcinoma (HNSCC). The key objectives are to: 1) examine the mechanism by which FOSL1 super-enhancers determine the functional properties of cisplatin-enriched CSCs, and...
The National Cancer Institute (NCI) awarded a $499,238 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to Yale University to develop a novel tumor-targeted STING agonist (PHLIP-STINGA) to enhance the effects of DNA-damaging cancer therapies in head and neck squamous cell carcinoma (HNSCC). The 5-year project aims to: 1) Optimize the PHLIP-STINGA formulation to overcome pharmacokinetic limitations of existing STING agonists; 2) Evaluate how PHLIP-STINGA synergizes with...
This $612,048 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to investigate the role of the lysyl oxidase propeptide (LOX-PP) in regulating macrophage phenotypes and their impact on oral squamous cell carcinoma (OSCC) tumor suppression. The research aims to characterize the differential effects of wildtype versus variant LOX-PP on macrophage activation,...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at unraveling the mechanisms driving metastasis in small cell lung cancer (SCLC). The research strategy integrates human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to investigate the cellular and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the lineage evolution and epigenomic signatures of a distinct subtype of small cell lung cancer (SCLC) characterized by the lineage factor NKX2-1. The research aims to: 1) Determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic subtype, 2) Elucidate the...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $170,208 to The Washington University to support a 4-year career development plan for R. Alex Harbison, MD. The objective is to prepare Dr. Harbison to become an independent physician-scientist focused on targeting polyamine metabolism to enhance immune responses against head and neck squamous cell carcinoma (HNSC). The...

STROMAL EFFECTS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA - SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (HNSCC) IS A COMPLEX DISORDER THAT CONTAINS MULTIPLE CELL POPULATIONS, MAKING IT IS DIFFICULT TO STUDY THE NATURE AND CELLULAR FUNCTION AND DELINEATE RELATIONSHIP AMONG SUBPOPULATIONS. THE ANALYSIS OF GLOBAL GENE EXPRESSIONS IN SINGLE CELL LEVEL HAS EVOLVED AT AN ASTOUNDING PACE IN THE PAST FEW YEARS, AND NOW REACHING A SOPHISTICATED LEVEL TO SOLVE HETEROGENEITY IN COMPLEX ORGANS. TO UNDERSTANDING THE IN VIVO TUMOR MICROENVIRONMENT, A LARGE SCALE (~10,000 CELLS) SINGLE CELL GENE EXPRESSION ASSAY CAN ELUCIDATE TRANSITIONAL STATES AND DELINEATE RELATIONSHIPS AMONG SUBPOPULATIONS. THE GOALS OF THIS PROPOSAL ARE TO CHARACTERIZE A DISTINCT POPULATION OF HNSCC STROMAL PROGENITORS, TO EXPLORE CELLULAR MECHANISMS BY WHICH THESE CELLS REGULATE TUMOR PROGRESSION, AND TO ULTIMATELY TRANSLATE THE FINDINGS INTO CLINICAL CANCER THERAPIES. USING GENETIC TOOLS AND SCC ANIMAL MODELS, DATA HAS BEEN GENERATED TO DEMONSTRATE THAT: 1) A UNIQUE POSTNATAL GLI1+ STROMAL POPULATION IS FOUND IN THE CRANIOFACIAL REGION, 2) GLI1+ CELLS BEHAVE AS PROGENITORS UNDER HOMEOSTATIC AND DISEASE CONDITIONS IN VIVO, 3) TUMOR PROGRESSION IS SUPPORTED BY STROMAL COMPONENTS THAT ARE ELEVATED IN HNSCC MICROENVIRONMENT AND SERVE AS A CHEMO- ATTRACTANT FOR TUMOR INVASION, AND 4) 3D CULTURE OF PRIMARY TUMOR KERATINOCYTES WITH CANCER ASSOCIATED FIBROBLASTS (CAFS) SHOWED THAT THE STRATIFIED GROWTH, CELL PROLIFERATION, AND DIFFERENTIATION ARE COMPARABLE BETWEEN CO-CULTURES AND THEIR RESPECTIVE NATIVE TISSUES, WHILE THEY LARGELY DIFFERED IN CULTURES WITHOUT CAFS. WE HYPOTHESIZE THAT GLI1+ CELLS CONTAIN A DISTINCT SUBPOPULATION OF STROMAL PROGENITORS IN THE CRANIOFACIAL REGION, AND THAT GLI1+ CELLS PLAY A NICHE ROLE IN SUPPORTING HNSCC PROGRESSION THROUGH REMODELING EPITHELIAL MORPHOGENESIS. DURING THIS PROPOSAL, WE WILL EXPLORE WHETHER GLI1+ CELLS AS A NICHE SUPPORT CANCER PROGRESSION AND METASTASIS THROUGH LINEAGE TRACING IN GLI1CREERT2;TDTOMATO MICE AND DIPHTHERIA-MEDIATED LOSS-OF-FUNCTION IN GLI1CREERT2;DTA MICE (AIM 1). SUBSEQUENTLY, THIS PROPOSAL WILL USE TRANSCRIPTOMIC AND SPATIAL MOLECULAR ANALYSIS IN SINGLE-CELL LEVEL COMBINED WITH COMPUTATIONAL ANALYSIS AND FUNCTIONAL VALIDATION TO IDENTIFY UNIQUE IN VIVO STROMAL POPULATIONS IN MOUSE AND HUMAN HNSCC AND ELUCIDATE THEIR MOLECULAR AND PATHWAY SIGNATURES. WE WILL VALIDATE THESE UNIQUE CANCER STROMAL SUBPOPULATIONS AND INVESTIGATE THEIR FEATURES, REGULATORY MECHANISM, FUNCTION, AND SPATIAL AND MOLECULAR CHARACTERISTICS. BASED ON THE FINDINGS, BY 3D ORGANOID MODELING WITH NOVEL VASCULARIZED ORGAN-ON-A CHIP TECHNIQUE, NEWLY IDENTIFIED TUMOR SPECIFIC STROMAL PROGENITOR POPULATIONS WILL BE UTILIZED TO GENERATE 3D VASCULARIZED SCC ORGANOIDS AND DISCOVER NOVEL THERAPEUTIC AVENUES FOR HNSCC MANAGEMENT (AIM 2). SUCCESSFUL COMPLETION OF THE PROPOSAL WILL ADVANCE OUR UNDERSTANDING OF THE NATURE OF IN VIVO STROMAL EFFECTS IN TUMOR MICROENVIRONMENT AND WILL DEVELOP NEW TREATMENTS FOR HNSCC.

Posted 6/5/24, 12:00 AM